Forest Admits To Knowingly Obstructing FDA Inspection In Guilty Pleas On Levothroid, Celexa Marketing
This article was originally published in The Pink Sheet Daily
Executive Summary
Forest Pharmaceuticals reached a $313 million settlement with the Department of Justice to resolve criminal charges of obstructing an FDA inspection and distributing a misbranded drug and civil False Claims Act allegations.
You may also be interested in...
Forest COPD Combo Hits Roadblock En Route To NDA Filing
Forest is delaying submission of an NDA for aclidinium/formoterol to resolve FDA concerns about the formulation’s chemistry, manufacturing and control specifications.
Forest COPD Combo Hits Roadblock En Route To NDA Filing
Forest is delaying submission of an NDA for aclidinium/formoterol to resolve FDA concerns about the formulation’s chemistry, manufacturing and control specifications.
Forest COPD Combo Hits Roadblock En Route To NDA Filing
Forest is delaying submission of an NDA for aclidinium/formoterol to resolve FDA concerns about the formulation’s chemistry, manufacturing and control specifications.